(Q86089687)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

meta-analysis

0 references

title

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

main subject

phase II clinical trial

1 reference

1 reference

José María del Campo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Cristiana Sessa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Carolyn N Krasner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Jan B Vermorken

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Nicoletta Colombo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Stan Kaye

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Martin Gore

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Patrik Zintl

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Javier Gómez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Trilok Parekh

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Youn Choi Park

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Scott McMeekin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

9 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

435

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23397080%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-012-0435-1

23 February 2020

exact match

0 references

cites work

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

1 reference

12 December 2020

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

12 December 2020

Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

1 reference

12 December 2020

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Oral etoposide for the treatment of recurrent ovarian cancer

1 reference

12 December 2020

Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer

1 reference

12 December 2020

Progress in the management of gynecologic cancer: consensus summary statement

1 reference

12 December 2020

Experience with bevacizumab in the management of epithelial ovarian cancer

1 reference

12 December 2020

Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

1 reference

12 December 2020

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

12 December 2020

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

1 reference

12 December 2020

Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer

1 reference

12 December 2020

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

1 reference

12 December 2020

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

1 reference

12 December 2020

Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer

1 reference

12 December 2020

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

1 reference

12 December 2020

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

1 reference

12 December 2020

A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy

1 reference

12 December 2020

Role of homologous recombination in trabectedin-induced DNA damage

1 reference

12 December 2020

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

1 reference

12 December 2020

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

1 reference

12 December 2020

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

12 December 2020

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

1 reference

12 December 2020

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

12 December 2020

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).

1 reference

12 December 2020

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

12 December 2020

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

12 December 2020

Management strategies for recurrent platinum-resistant ovarian cancer

1 reference

12 December 2020

A review of trabectedin (ET-743): a unique mechanism of action.

1 reference

12 December 2020

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

1 reference

12 December 2020

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

1 reference

12 December 2020

Liposomal anthracycline treatment for ovarian cancer

1 reference

12 December 2020

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

12 December 2020

A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study

1 reference

12 December 2020

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

12 December 2020

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020